Should aspirin (acetylsalicylic acid) be held before a skin biopsy?

Do Not Hold Aspirin Prior to Skin Biopsy

Aspirin does not need to be stopped before a skin biopsy in most patients, as this is a minor dermatologic procedure with low bleeding risk that can be safely performed while continuing antiplatelet therapy.

Evidence-Based Recommendation

The most recent and highest-quality guideline evidence directly addresses this question. The 2022 American College of Chest Physicians (ACCP) clinical practice guideline specifically recommends continuing aspirin for minor dermatologic procedures rather than stopping it beforehand 1. This represents the current standard of care for procedural antiplatelet management.

Supporting Guideline Evidence

Multiple international guidelines converge on the safety of continuing aspirin for low-risk procedures:

• Minor dermatologic procedures are classified as low bleeding risk procedures where antiplatelet interruption is unnecessary 1
• The ACCP guideline suggests continuing both aspirin and P2Y12 inhibitors (like clopidogrel) for minor dermatologic procedures, though patients on dual antiplatelet therapy can continue aspirin and interrupt the P2Y12 inhibitor if desired 1
• For patients on dual antiplatelet therapy with coronary stents, aspirin should definitely be continued to prevent catastrophic thrombotic events 2

Clinical Context from Liver Biopsy Guidelines

While skin biopsies carry even lower bleeding risk than liver biopsies, the British Society of Gastroenterology's 2020 liver biopsy guidelines provide useful context: they recommend that stopping aspirin 3 days prior to percutaneous biopsy should be considered for liver biopsies specifically, but note this decision depends on the urgency and the indication for aspirin 3. Importantly, they acknowledge that "pausing aspirin may not be necessary and should be at the discretion of the operator if urgent" 3.

Risk-Benefit Analysis

Bleeding Risk with Aspirin Continuation

The actual bleeding risk from skin biopsies while on aspirin is minimal:

• Older research from 1996 noted that aspirin-induced bleeding complications occurred in approximately 15% of skin surgery patients, but these were minor complications, not serious bleeding events 4
• The same study found that patients with bleeding times >8 minutes were at higher risk, but routine bleeding time testing is not recommended in modern practice 4
• Skin biopsies involve minimal tissue disruption compared to other procedures and are easily compressible

Thrombotic Risk with Aspirin Interruption

The risks of stopping aspirin can be substantial:

• For secondary prevention (patients with prior cardiovascular events), aspirin should not be routinely stopped 2
• Interrupting aspirin in patients with recent coronary stents can lead to catastrophic stent thrombosis, myocardial infarction, or death
• The thrombotic risk from stopping aspirin typically outweighs the minimal bleeding risk from a skin biopsy

Practical Algorithm

For patients on aspirin requiring skin biopsy:

1. Continue aspirin - This is the default approach for routine skin biopsies
2. Assess cardiovascular risk - Determine if aspirin is for primary or secondary prevention
3. If secondary prevention (prior MI, stroke, stents): Absolutely continue aspirin
4. If primary prevention only: Can consider stopping aspirin if there are specific patient factors increasing bleeding risk, but this is rarely necessary
5. Apply local hemostatic measures - Use appropriate technique, pressure, and hemostatic agents as needed

Important Caveats

• This recommendation applies to standard punch or shave biopsies - not extensive excisional procedures
• For patients on dual antiplatelet therapy (aspirin + clopidogrel/prasugrel/ticagrelor), continue at least the aspirin; the P2Y12 inhibitor can be held if there are concerns, but consult cardiology for patients with recent stents
• P2Y12 inhibitors alone (clopidogrel, prasugrel, ticagrelor) can also be continued for minor dermatologic procedures per ACCP guidelines 1, though they have longer washout periods (7 days) if interruption is deemed necessary
• Ensure adequate local hemostasis techniques are employed regardless of antiplatelet status

Common Pitfalls to Avoid

1. Do not reflexively stop aspirin for all procedures - this outdated practice increases thrombotic risk unnecessarily
2. Do not stop aspirin in patients with coronary stents without cardiology consultation - the consequences can be fatal
3. Do not confuse skin biopsy with higher-risk dermatologic surgery - extensive excisions may warrant different management
4. Do not rely on bleeding time tests - these are not predictive of procedural bleeding risk in modern practice

The evidence strongly supports continuing aspirin for skin biopsies, prioritizing patient safety by preventing thrombotic complications while accepting the minimal and manageable bleeding risk.